UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase III Randomized Intergroup Trial of Subtotal Lymphoid Irradiation Versus Doxorubicin, Vinblastine, and Subtotal Lymphoid Irradiation for Stage IA to IIA Hodgkin’s Disease

Journal of clinical oncology, 2001-11, Vol.19 (22), p.4238-4244

2001

Volltextzugriff (PDF)

Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma

The New England journal of medicine, 1993-04, Vol.328 (14), p.1002-1006

1993

Volltextzugriff (PDF)

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma

Journal of clinical oncology, 1992-02, Vol.10 (2), p.275-281

1992

Volltextzugriff (PDF)

Infusional CHOP Chemotherapy (CVAD) With or Without Chemosensitizers Offers No Advantage Over Standard CHOP Therapy in the Treatment of Lymphoma: A Southwest Oncology Group Study

Journal of clinical oncology, 2001-02, Vol.19 (3), p.750-755

2001

Volltextzugriff (PDF)

A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study

Annals of oncology, 1994, Vol.5 (suppl-2), p.S91-S95

1994

Volltextzugriff (PDF)

Daily Subcutaneous Ultra-Low-Dose Interleukin 2 with Daily Low-Dose Interferon-α in Patients with Advanced Renal Cell Carcinoma

Clinical cancer research, 1999-09, Vol.5 (9), p.2374-2380

1999

Volltextzugriff (PDF)

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

Annals of internal medicine, 1988-12, Vol.109 (12), p.953

1988

Volltextzugriff (PDF)

Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen

Journal of clinical oncology, 1990-10, Vol.8 (10), p.1630-1636

1990

Volltextzugriff (PDF)

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma

Journal of clinical oncology, 1991-04, Vol.9 (4), p.641-648

1991

Volltextzugriff (PDF)

Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma

Journal of immunotherapy (1997), 1994-02, Vol.15 (2), p.147-153

1994

Volltextzugriff (PDF)

Phase I Study of High-Dose Continuous-Infusion Recombinant Interleukin-2 and Autologous Lymphokine-Activated Killer Cells in Patients With Metastatic or Unresectable Malignant Melanoma and Renal Cell Carcinoma

JNCI : Journal of the National Cancer Institute, 1990-09, Vol.82 (17), p.1397-1402

1990

Volltextzugriff (PDF)

Prognostic significance of the Ki-67 : associated proliferative antigen in aggressive non-Hodgkin's lymphomas : a prospective Southwest oncology group trial

Blood, 1994-03, Vol.83 (6), p.1460-1466

1994

Volltextzugriff (PDF)

Colosplenic fistula in a patient treated with interleukin-2 for malignant melanoma

Journal of computer assisted tomography, 1997-07, Vol.21 (4), p.674

1997

Volltextzugriff (PDF)

CHOP Therapy: Has Shorter-Course Therapy Had an Impact on Lymphomas?

Cancer investigation, 1998, Vol.16 (1), p.26-32

1998

Volltextzugriff (PDF)

Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors

Journal of immunotherapy (1997), 1994-10, Vol.16 (3), p.216-223

1994

Volltextzugriff (PDF)

Clinical trials of alpha-interferon in the treatment of non-Hodgkin's lymphoma

Seminars in oncology, 1991-10, Vol.18 (5 Suppl 7), p.12

1991

Volltextzugriff (PDF)

Long-term survival of patients with localized diffuse histiocytic lymphoma

Journal of clinical oncology, 1985-10, Vol.3 (10), p.1309-1317

1985

Volltextzugriff (PDF)

Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, oncovin, methotrexate, leucovorin, cytosine arabinoside): a 10-year experience in a single institution

Journal of clinical oncology, 1985-12, Vol.3 (12), p.1596-1604

1985

Volltextzugriff (PDF)

Low‐dose cytosine arabinoside (Ara‐C) therapy in the myelodysplastic syndromes and acute leukemia

Cancer, 1985-08, Vol.56 (3), p.443-449

1985

Volltextzugriff (PDF)

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

Blood, 2003-09, Vol.102 (5), p.1606-1612

2003

Volltextzugriff (PDF)

Prevalence of secondary causes of bone loss in patients with breast cancer initiating treatment on clinical trials with aromatase inhibitors or bisphosphonates

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e11019-e11019

2010

Volltextzugriff (PDF)

Abstract P2-11-13: The 70-gene signature (70-GS) in a lymph node-negative patient series with intermediate risk 21-gene recurrence scores (RS) and known adjuvant treatment recommendations

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P2-P2-11-13

2013

Volltextzugriff (PDF)

Chemotherapy of intermediate-grade non-Hodgkin's lymphoma: is "more" or "less" better?

Oncology (Williston Park, N.Y.), 1995-12, Vol.9 (12), p.1273

1995

Volltextzugriff (PDF)

Health Status and Quality of Life in Patients With Early-Stage Hodgkin’s Disease Treated on Southwest Oncology Group Study 9133

Journal of clinical oncology, 2003-09, Vol.21 (18), p.3512-3519

2003

Volltextzugriff (PDF)

Abstract PD10-02: Metabolic syndrome and recurrence within the 21-gene recurrence score assay risk categories in lymph node negative breast cancer

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.PD10-02-PD10-02

2012

Volltextzugriff (PDF)

1 – 25 von 426

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(387)
Mit Volltextzugriff
(343)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(426)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase III Randomized Intergroup Trial of Subtotal Lymphoid Irradiation Versus Doxorubicin, Vinblastine, and Subtotal Lymphoid Irradiation for Stage IA to IIA Hodgkin’s Disease

Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma

Infusional CHOP Chemotherapy (CVAD) With or Without Chemosensitizers Offers No Advantage Over Standard CHOP Therapy in the Treatment of Lymphoma: A Southwest Oncology Group Study

A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study

Daily Subcutaneous Ultra-Low-Dose Interleukin 2 with Daily Low-Dose Interferon-α in Patients with Advanced Renal Cell Carcinoma

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma

Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma

Phase I Study of High-Dose Continuous-Infusion Recombinant Interleukin-2 and Autologous Lymphokine-Activated Killer Cells in Patients With Metastatic or Unresectable Malignant Melanoma and Renal Cell Carcinoma

Prognostic significance of the Ki-67 : associated proliferative antigen in aggressive non-Hodgkin's lymphomas : a prospective Southwest oncology group trial

Colosplenic fistula in a patient treated with interleukin-2 for malignant melanoma

CHOP Therapy: Has Shorter-Course Therapy Had an Impact on Lymphomas?

Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors

Clinical trials of alpha-interferon in the treatment of non-Hodgkin's lymphoma

Long-term survival of patients with localized diffuse histiocytic lymphoma

Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, oncovin, methotrexate, leucovorin, cytosine arabinoside): a 10-year experience in a single institution

Low‐dose cytosine arabinoside (Ara‐C) therapy in the myelodysplastic syndromes and acute leukemia

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

Prevalence of secondary causes of bone loss in patients with breast cancer initiating treatment on clinical trials with aromatase inhibitors or bisphosphonates

Abstract P2-11-13: The 70-gene signature (70-GS) in a lymph node-negative patient series with intermediate risk 21-gene recurrence scores (RS) and known adjuvant treatment recommendations

Chemotherapy of intermediate-grade non-Hodgkin's lymphoma: is "more" or "less" better?

Health Status and Quality of Life in Patients With Early-Stage Hodgkin’s Disease Treated on Southwest Oncology Group Study 9133

Abstract PD10-02: Metabolic syndrome and recurrence within the 21-gene recurrence score assay risk categories in lymph node negative breast cancer

Suchergebnisse filtern